CellSeed Inc. (7776.T)
JPY 408.0
(-7.69%)
JPY 408.0
(-7.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 804.93 Million JPY | 0.09% |
| 2022 | 804.23 Million JPY | -15.18% |
| 2021 | 948.14 Million JPY | 10.54% |
| 2020 | 857.7 Million JPY | -17.73% |
| 2019 | 1.04 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 255.37 Million JPY | 1.94% |
| 2024 Q1 | 250.51 Million JPY | 54.95% |
| 2023 Q2 | 200.43 Million JPY | 1.65% |
| 2023 Q4 | 161.67 Million JPY | -34.18% |
| 2023 FY | 804.93 Million JPY | 0.09% |
| 2023 Q1 | 197.19 Million JPY | 0.11% |
| 2023 Q3 | 245.62 Million JPY | 22.54% |
| 2022 Q3 | 222.36 Million JPY | 0.0% |
| 2022 FY | 804.23 Million JPY | -15.18% |
| 2022 Q4 | 196.98 Million JPY | -11.41% |
| 2021 FY | 948.14 Million JPY | 10.54% |
| 2020 FY | 857.7 Million JPY | -17.73% |
| 2019 FY | 1.04 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 37.334% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -39.548% |
| GNI Group Ltd. | 9.32 Billion JPY | 91.366% |
| Linical Co., Ltd. | 2.7 Billion JPY | 70.245% |
| Trans Genic Inc. | 2.15 Billion JPY | 62.732% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 46.02% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 73.79% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 56.654% |
| AnGes, Inc. | 8.9 Billion JPY | 90.958% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | 14.649% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 95.805% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -94.903% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 17.474% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 68.65% |
| CanBas Co., Ltd. | 278 Million JPY | -189.544% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 29.487% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 55.723% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 49.81% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 66.095% |
| PeptiDream Inc. | 9.68 Billion JPY | 91.691% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 58.944% |
| Ribomic Inc. | 1.1 Billion JPY | 27.201% |
| SanBio Company Limited | 4.53 Billion JPY | 82.266% |
| Healios K.K. | 3.48 Billion JPY | 76.916% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 30.293% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 39.681% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 42.647% |
| StemRIM | 2.07 Billion JPY | 61.227% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 59.005% |
| FunPep Company Limited | 313.82 Million JPY | -156.494% |
| Kringle Pharma, Inc. | 958.01 Million JPY | 15.979% |
| Stella Pharma Corporation | 963.98 Million JPY | 16.5% |
| TMS Co., Ltd. | 943.25 Million JPY | 14.664% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 26.15% |
| Cuorips Inc. | 598.11 Million JPY | -34.577% |
| K Pharma,Inc. | 543.94 Million JPY | -47.981% |
| Takara Bio Inc. | 23.9 Billion JPY | 96.633% |
| ReproCELL Incorporated | 1.51 Billion JPY | 46.835% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 32.015% |
| StemCell Institute Inc. | 1.16 Billion JPY | 30.736% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 47.123% |